Promising drug duo before bladder removal shows hope for advanced cancer patients
NCT ID NCT06764095
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a targeted drug (enfortumab vedotin) plus an immunotherapy (pembrolizumab) before surgery to remove part or all of the bladder can improve outcomes for people with advanced bladder or urinary tract cancer. About 75 adults with cancer that has spread to nearby tissues or other parts of the body will receive standard treatment followed by surgery. The goal is to see if this approach helps keep cancer from growing longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BLADDER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody-drug combo tackle rare bladder cancers?
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New strategy aims to eliminate residual bladder cancer after drug combo
- New hope for bladder cancer patients who Can't take chemo
- Experimental triple therapy for advanced cancers shows early promise but trial halted